Researchers evaluated data from the EXSCEL study involving 10,782 participants with type 2 diabetes and cardiovascular disease and found that those who received exenatide 2 mg injection once a week had a 10% relative risk reduction for major adverse CV events, such as CV death, nonfatal stroke and nonfatal myocardial infarction, compared with those on placebo. The findings, presented at the Heart in Diabetes conference and published in Circulation, also showed that all-cause mortality rate was lower in the exenatide group.
Type 2 diabetes patients with CVD benefited from once-weekly exenatide
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.